Enhertu won its initial China nod in early 2023 as a treatment for previously treated HER2-positive breast cancer and later ...
GSK has made another trip to China to build out its antibody-drug conjugate (ADC) pipeline, returning with an option on a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback